Case Reports in Neurological Medicine

Case Reports in Neurological Medicine / 2019 / Article

Case Report | Open Access

Volume 2019 |Article ID 9185603 |

Laura N. Zamproni, Reinaldo T. Ribeiro, Marina Cardeal, "Treatment of Recurrent Painful Ophthalmoplegic Neuropathy: A Case Where Pregabalin Was Successfully Employed", Case Reports in Neurological Medicine, vol. 2019, Article ID 9185603, 5 pages, 2019.

Treatment of Recurrent Painful Ophthalmoplegic Neuropathy: A Case Where Pregabalin Was Successfully Employed

Academic Editor: Mehmet Turgut
Received22 Oct 2018
Accepted27 Jan 2019
Published07 Feb 2019


Recurrent painful ophthalmoplegic neuropathy, previously known as ophthalmoplegic migraine, is a rare condition that affects children and young adults. Its cause and classification are still controversial and, consequently, there are no published treatment guidelines or consensus. Glucocorticoids seem to be beneficial for some patients, but there is no established treatment when failure of this therapy occurs. The aim of this study was to report a case where pregabalin was successfully used after failure of glucocorticoid therapy in a patient with recurrent painful ophthalmoplegic neuropathy.

1. Introduction

Recurrent painful ophthalmoplegic neuropathy (RPON), previously known as ophthalmoplegic migraine (OM), is a rare condition (estimated annual incidence of 0,7 per million) involving headache and ophthalmoplegia, which typically occurs in children and young adults [1]. Typical features include repeated attacks of paralysis of one or more ocular cranial nerves (III, IV, or VI) with ipsilateral headache that can start up to two weeks before the onset of eye muscle weakness [15]. The International Classification of Headache Disorders 3rd edition-beta version (ICHD3β) defined the following diagnostic criteria for RPON: (1) at least two attacks; (2) unilateral headache accompanied by ipsilateral paresis of one, two, or three ocular motor nerves; (3) the exclusion of orbital, parasellar, or posterior fossa lesions by an appropriate investigation; and (4) the absence of another diagnosis that could better account for the patient's condition [16].

RPON was used to be classified as a migraine variant, but the disease concept has changed due to lack of migraine symptoms in many cases and evidence supporting neuropathy [1]. Brain MRI reveals gadolinium enhancement of the affected cranial nerve in approximately 75 % of patients suggesting that the condition is a demyelinating disorder [15]. However, the cause and classification remain controversial.

This lack of information about the disease pathophysiology makes the treatment even more controversial. In fact, there are very few data or consensus about RPON treatment. The aim of this study is to report a case where pregabalin was successfully employed after glucocorticoid therapy failure in RPON.

2. Case Report

A 21-year-old female patient came to our service with a complaint of unilateral right-onset headache associated with diplopia initiated 6 months earlier. She had no personal or family remarkable antecedents. She never smoked. Six months earlier, the patient started to experience one-sided right throbbing headache. She denied nausea, vomiting, or photo- or phonophobia. Fifteen days after the pain onset, she noticed double vision and medial deviation of the right eye, which forced her to wear an eyepiece to perform her activities and drive. She went to several centers and used various medications such as paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and triptans without improvement. Three months earlier, she started using dexamethasone 4 mg daily with partial pain control but maintenance of diplopia.

At the examination, the patient had cushingoid face, violaceous striae, and right VI cranial nerve palsy with no other neurological changes. Blood tests were normal (Table 1). A contrast-enhanced MRI scan of the brain did not show any remarkable features (Figure 1). A spinal tap released crystalline cerebrospinal fluid (CSF) with an opening pressure of 14 cm of water. Biochemical, microbiological, and cytological analyses of the CSF were normal (Table 1). CT scan of thorax did not show any evidence of lymphoma or sarcoidosis.

Hemoglobin (g/dL)13.1

WBC (/mm3)12700

Platelets (/mm3)298000

Na (mmol/L)141

K (mmol/L)4,1

Coagulation testsNormal

Creatinine (mg/dL)0,5

CPK (U/L)38

ESR (mm/h)22

Bilirubin (mg/dL)0,27

AST (U/L)16

ALT (U/L)18


GGT (U/L)47

TSH (um/L)0,8









ACE (U/L)31

VDRL testNegative

Cerebrospinal fluid

 WBC (/mm3)1

 Protein (mg/dL)22

 Glucose (mg/dL)66


WBC: white blood cells; Na: sodium; K: potassium; ESR: erythrocyte sedimentation rate; CPK: creatine phosphokinase; AST: aspartate aminotransferase; ALT: alanine transaminase; ALP: alkaline phosphatase;  GGT: gamma glutamyl transferase; TSH: thyroid stimulating hormone; ANA: antinuclear antibodies; Anti-dsDNA: anti-double stranded DNA antibodies; HIV: human immunodeficiency virus; ACE: angiotensin-converting enzyme; ANCA: anti-neutrophil cytoplasmic antibody; VDRL test: Venereal Disease Research Laboratory test.

Prednisone 1mg / kg was then started. With one week of treatment, complete reversal of ocular paralysis and remission of pain were observed. However, when the corticoid was gradually withdrawn, the patient returned to pain and returned to paralysis of the VI right pair. The prednisone was increased again to 1 mg / kg this time with reversion of ocular paralysis but without pain control. Several prophylaxis attempts were made with beta-blockers, calcium channel blockers, topiramate, and tricyclics without any symptomatic control that would allow corticosteroid withdrawal.

The pregabalin 150mg daily was then introduced. With 7 days of medication onset there was already an important remission of pain. With 15 days of pregabalin initiation, the retitration of prednisone was started without any intercurrence and the patient reversed the exogenous Cushing syndrome. Pregabalin was maintained for one year and retracted. Currently, the patient has been free of pain for 2 years.

3. Discussion

According to the prevailing diagnostic criteria, our patients suffered from RPON given the presence of a documented VI nerve palsy associated with a unilateral ipsilateral headache with no remarkable alterations in laboratory or neuroimaging exams. Although the enhancement of the affected nerve occurs in 75% of patients [15], brain MRI is normal in a quarter of cases. We emphasize that our patient had been using a lower dose of corticosteroids for almost 3 months before admission, which may have reduced the sensitivity of the exam (Figure 1). Our patient responded partially to corticosteroids and absolutely to pregabalin but not to other treatment.

Since RPON is a very rare condition, it is difficult to conduct studies. There are no published treatment trials or guidelines for RPON and all evidence of effective treatments came from observational studies. Glucocorticoids seem to be beneficial for some patients. Prompt administration of steroids at the clinical onset may minimize permanent ophthalmoparesis or pupillary disfunction [17]. In a retrospective review of 80 patients, steroids were used to treat at least 31% of patients and there was a perceived benefit from corticosteroid treatment in 54 %. Only 12 % had no improvement or clinical worsening [15].

For those patients that do not respond to corticosteroids, treatment evidence is even smaller. The efficacy of drugs for migraine such as acetaminophen, NSAIDs, ergotamine, and triptans is unknown [1]. Pareja et al. described two cases of PRON responsive to indomethacin [18]. Also, cyproheptadine hydrochloride has been reported to prevent recurrent attacks of RPON by targeting the vascular edema around the oculomotor nerve [1].

Some authors recommend standard migraine prophylactic therapy for patients with recurrent attacks. We searched PubMed for case reports published between 2103 and 2017 using the search terms “ophthalmoplegic migraine” and “recurrent painful ophthalmoplegic neuropathy”. We found 10 case reports that are displayed at Table 2. After steroids, valproate and topiramate were the most prescribed medication. Both valproate and topiramate increase gamma-aminobutyric acid (GABA) levels in the brain and are first-line agents in migraine prevention (Table 3) [13].

AuthorPatient age/ genderPain descriptionNerve palsyTreatmentTime to fully recovery

Kobayashi et al. 2017 [1]48-year-old /femaleUnilateral  
Photophobia Phonophobia
Incomplete III pairCorticosteroids5 days  
Persistent Residual Mydriasis

Qureshi et al. 2017 [2]53-year-old / femaleUnilateral  
Photophobia Phonophobia
Incomplete III pairNSAIDs  
Serotonin receptor agonist  
Calcium channel blocker

Huang et al. 2017 [3]26-year-old / femaleUnilateralIncomplete III pairCorticosteroids Topiramate6 weeks

Tripathi et al. 2017 [4]36-year old / femaleUnilateral  
VI pairGabapentin  
2 months

Okura et al. 2017 [5]12-year-old / maleUnilateralIncomplete III pairCorticosteroids8 weeks

Takizawa et al. 2016 [6]42-year-old / femaleUnilateral  
Incomplete III pairNRNR

Ghosh 2015 [7]5-year-old / maleUnilateralIncomplete III pairCorticosteroids  
3 weeks

Ramakrishnan et al. 2015 [8]30-year-old / femaleUnilateral  
Photophobia Phonophobia
Incomplete III pairValproate Corticosteroids1 month

Wang et al. 2014 [9]63-year-old / maleUnilateral  
Incomplete III pairValproate  

Shetty et al. 2013 [10]26-year-old / femaleUnilateral  
Incomplete III pairNSAIDs Propranolol2 weeks

NR: not reported; NSAIDs: nonsteroidal anti-inflammatory drugs.

Drug Mechanism of action

Corticosteroidsinhibit the synthesis of inflammatory proteins, induce the expression of anti-inflammatory proteins and inhibit cyclooxygenase-2 [11]

Indomethacininhibition of cyclooxygenase 1 and cyclooxygenase 2 and phospholipase A2 [12]

Valproateincreases gamma-aminobutyric acid (GABA) levels in synaptosomes and in the brain, reduces the central trigeminal nerve activation (by increasing GABA levels), was shown to reduce experimental neurogenic inflammation in the peripheral trigeminal vascular system [13]

Topiramatemodifies the excitability of nerves by blocking voltage-sensitive sodium channels and L-type voltage-activated calcium channels, inhibits carbonic anhydrase activity, inhibits the excitatory glutamate pathway while enhancing the inhibitory effect of GABA [13]

Pregabalinbinds to alpha 2-delta subunits of the voltage-gated calcium cannels in the nervous system, reducing the influx of calcium in the presynaptic ending, and, consequently, reduces the release of excitatory neurotransmitters including glutamate, noradrenaline, dopamine, and serotonin in the synaptic cleft [14]

In more refractory cases, injection of botulinum toxin or strabismus surgery may be considered for patients with persistent sequelae, to correct eye misalignment [15].

As far as we know, pregabalin has not been reported for RPON treatment. Pregabalin is a structural analogue of GABA. Pregabalin binds to alpha 2-delta subunits of the voltage-gated calcium cannels in the nervous system, reducing the influx of calcium in the presynaptic ending, and, consequently, reduces the release of excitatory neurotransmitters including glutamate, noradrenaline, dopamine, and serotonin in the synaptic cleft [14]. Pregabalin has been used to treat neuropathic pain. The response to pregabalin and the lack of efficacy of classic drugs used in migraine, such as NSAIDs and first-line prophylactic migraine drugs (topiramate and valproate) in this case, reinforce the neuropathic etiology of the disease and not a variant of migraine as it was formerly classified.

Informed consent has been obtained from the patient for this report.


No funding sources are involved in this paper.

Conflicts of Interest

The authors have no conflicts of interest to declare.


  1. Y. Kobayashi, Y. Kondo, K. Uchibori, and J. Tsuyuzaki, “Recurrent painful ophthalmoplegic neuropathy with residual mydriasis in an adult: Should it be classified as ophthalmoplegic migraine?” Internal Medicine, vol. 56, no. 20, pp. 2769–2772, 2017. View at: Publisher Site | Google Scholar
  2. I. A. Qureshi, G. J. Rodriguez, S. Cruz-Flores, and A. Maud, “Persistent focal enhancement of the cisternal segment of oculomotor nerve in ophthalmoplegic migraine,” Neurology: Clinical Practice, vol. 7, no. 5, pp. 381–383, 2017. View at: Publisher Site | Google Scholar
  3. C. Huang, M. Amasanti, B. Lovell, and T. Young, “Recurrent painful ophthalmoplegic neuropathy,” Practical Neurology, vol. 17, no. 4, pp. 318–320, 2017. View at: Publisher Site | Google Scholar
  4. R. Tripathi, A. Tselis, and E. Bernitsas, “Bilateral cisternal abducens nerve involvement with ophthalmoplegic migraine,” Cephalalgia, vol. 37, no. 12, pp. 1211-1212, 2017. View at: Publisher Site | Google Scholar
  5. Y. Okura, A. Wakayama, C. Yoshizawa, I. Kobayashi, and Y. Takahashi, “Recurrent painful ophthalmoplegic neuropathy in a 12-year-old boy,” Pediatrics International, vol. 59, no. 11, pp. 1208–1210, 2017. View at: Publisher Site | Google Scholar
  6. T. Takizawa, M. Shibata, H. Fujiwara, T. Shimizu, S. Momoshima, and N. Suzuki, “Adult-onset recurrent painful ophthalmoplegic neuropathy displaying atypical oculomotor nerve gadolinium-enhancement pattern in the orbit and cavernous sinus,” Cephalalgia, vol. 36, no. 2, pp. 199-200, 2016. View at: Publisher Site | Google Scholar
  7. P. S. Ghosh, “Recurrent right-sided ptosis in a child,” JAMA Pediatrics, vol. 169, no. 7, pp. 693-694, 2015. View at: Publisher Site | Google Scholar
  8. S. Ramakrishnan, P. Kallollimath, G. B. Kulkarni, and V. Mustare, “Transient oculomotor synkinesis in a case of ophthalmoplegic migraine,” Neurology India, vol. 63, no. 5, pp. 778–780, 2015. View at: Publisher Site | Google Scholar
  9. Y. Wang, X.-H. Wang, M.-M. Tian et al., “Ophthalmoplegia starting with a headache circumscribed in a line-shaped area: a subtype of ophthalmoplegic migraine?” The Journal of Headache and Pain, vol. 15, no. 1, pp. 1–4, 2014. View at: Publisher Site | Google Scholar
  10. A. Shetty, S. Khardenavis, and A. Deshpande, “Ophthalmoplegic migraine with isolated third cranial nerve palsy in a known case of juvenile myoclonic epilepsy,” BMJ Case Reports, 2013. View at: Google Scholar
  11. M. Ciriaco, P. Ventrice, G. Russo et al., “Corticosteroid-related central nervous system side effects,” Journal of Pharmacology and Pharmacotherapeutics, vol. 4, no. 5, pp. 94–98, 2013. View at: Publisher Site | Google Scholar
  12. O. Summ and S. Evers, “Mechanism of action of indomethacin in indomethacin-responsive headaches,” Current Pain and Headache Reports, vol. 17, no. 4, article 327, 2013. View at: Publisher Site | Google Scholar
  13. R. Shahien and K. Beiruti, “Preventive agents for migraine: Focus on the antiepileptic drugs,” Journal of Central Nervous System Disease, vol. 4, pp. 37–49, 2012. View at: Publisher Site | Google Scholar
  14. S. M. Cain, B. Bohnet, J. LeDue et al., “In vivo imaging reveals that pregabalin inhibits cortical spreading depression and propagation to subcortical brain structures,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 114, no. 9, pp. 2401–2406, 2017. View at: Publisher Site | Google Scholar
  15. A. A. Gelfand, J. M. Gelfand, P. Prabakhar, and P. J. Goadsby, “Ophthalmoplegic "migraine" or recurrent ophthalmoplegic cranial neuropathy: New cases and a systematic review,” Journal of Child Neurology, vol. 27, no. 6, pp. 759–766, 2012. View at: Publisher Site | Google Scholar
  16. Headache Classification Committee of the International Headache Society (IHS), “The international classification of headache disorders, 3rd edition (beta version),” Cephalalgia, vol. 33, no. 9, pp. 629–808, 2013. View at: Publisher Site | Google Scholar
  17. B. D. Arasho, “Ophthalmoplegic migraine in a 15-year-old Ethiopian: Case report and literature review,” The Journal of Headache and Pain, vol. 10, no. 1, pp. 45–49, 2009. View at: Publisher Site | Google Scholar
  18. J. A. Pareja, J. Churruca, B. De La Casa Fages, C. L. De Silanes, C. Sánchez, and F. J. Barriga, “Ophthalmoplegic migraine. Two patients with an absolute response to indomethacin,” Cephalalgia, vol. 30, no. 6, pp. 757–760, 2010. View at: Publisher Site | Google Scholar

Copyright © 2019 Laura N. Zamproni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.